Overview

Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER

Status:
Active, not recruiting
Trial end date:
2023-11-09
Target enrollment:
Participant gender:
Summary
This is a multicenter open-label study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM) who previously participated in study MYK-461-004 (PIONEER-HCM).
Phase:
Phase 2
Details
Lead Sponsor:
MyoKardia, Inc.